COMP <GO>
JAZZ vs SMMT // ALTMAN Z-SCORE & DEBT/EQUITY
Jazz Pharmaceuticals plc (Ireland) (NASDAQ) VS. Summit Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: JAZZ 7
— SMMT 4
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: SMMT
LAST: $214.44 (-0.71%) • MKT CAP: $14.02B
balance-sheet
1.97
LAST: $14.80 (-7.67%) • MKT CAP: $12.82B
balance-sheet
26.00
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JAZZ VS. SMMT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | JAZZ | SMMT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -4.70% | -35.00% | +30.30 | JAZZ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 9.61% | -2.50% | +12.11 | JAZZ | /fcf-yield <GO> |
| Operating Margin | -10.10% | -36.30% | +26.20 | JAZZ | /operating-margins <GO> |
| Net Profit Margin | -8.30% | -29.80% | +21.50 | JAZZ | /net-margins <GO> |
| Revenue Growth (YoY) | 4.90% | 11.00% | -6.10 | SMMT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 1.97 | 26.00 | -24.03 | SMMT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 5/9 | +2.00 | JAZZ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.5 | 50.5 | -2.00 | SMMT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.09 | 0.97 | +0.12 | JAZZ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.0x | 34.0x | +2.00 | SMMT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.02B | $12.82B | $1.20B | JAZZ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | JAZZ REV | SMMT REV | JAZZ GROSS % | SMMT GROSS % | JAZZ FCF | SMMT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.27B | $3.57B | — | — | $1.30B | -$323.6M |
| FY 2024 | $4.07B | $632.8M | — | — | $1.36B | -$142.2M |
| FY 2023 | $3.83B | $1.71B | — | — | $919.5M | -$76.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JAZZ // BETA 1.09
SMMT // BETA 0.97